KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Other Operating Expenses: 2009-2024

Historic Other Operating Expenses for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $10.0 million.

  • Biomarin Pharmaceutical's Other Operating Expenses fell 6.77% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $153.8 million, marking a year-over-year increase of 1815.71%. This contributed to the annual value of $10.0 million for FY2024, which is 126.17% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Other Operating Expenses stood at $10.0 million for FY2024, which was up 126.17% from -$38.2 million recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Other Operating Expenses registered a high of $108.0 million during FY2022, and its lowest value of -$38.2 million during FY2023.
  • Over the past 3 years, Biomarin Pharmaceutical's median Other Operating Expenses value was $10.0 million (recorded in 2024), while the average stood at $26.6 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first spiked by 811.70% in 2022, then slumped by 135.38% in 2023.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Other Operating Expenses stood at $52.8 million in 2020, then plummeted by 77.57% to $11.8 million in 2021, then skyrocketed by 811.70% to $108.0 million in 2022, then slumped by 135.38% to -$38.2 million in 2023, then surged by 126.17% to $10.0 million in 2024.